In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

CRISPR technology has revolutionized genetic testing and disease detection, offering precise, rapid, and cost-effective diagnostic solutions. This gene-editing tool has been adapted for molecular ...

CRISPR Therapeutics AG (CRSP) closed at $43.42 in the latest trading session, marking a -1.83% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.29%.

On multiple occasions, Kennedy has commented on the potential of CRISPR, a potent and powerful gene-editing tool, to disrupt DNA in unintended and unsafe ways. The nonprofit that RFK Jr. founded ...

Zhi-Kun Li at the Chinese Academy of Sciences in Beijing and his colleagues used CRISPR to create the mice, using a novel approach to target genes that normally need to be inherited from both male ...

After hours: February 14 at 7:59:27 PM EST Loading Chart for CRSP ...

Partnerships allow Crispr Therapeutics to receive milestones and economic benefits from drug candidate progression while offsetting some of the clinical development costs.

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

Kennedy Jr. will di­vest his in­ter­ests in sev­er­al bio­phar­ma com­pa­nies, in­clud­ing CRISPR Ther­a­peu­tics and Drag­on­fly Ther­a­peu­tics, if con­firmed by the ...